MedeliX
Start asking

Crisantaspase

Enrylaze · ATC code L01XX02

Key facts
Active substance
Crisantaspase
ATC code
L01XX02
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Enrylaze 10 mg/0.5 mL solution for injection/infusion.
Marketing authorisation holder
Jazz Pharmaceuticals Ireland Limited
Information as of
2026-10-27

Key facts

Crisantaspase (Enrylaze) is a recombinant Erwinia chrysanthemi asparaginase. It is used as part of multi-agent chemotherapy for acute lymphoblastic leukaemia and lymphoblastic lymphoma after hypersensitivity or silent inactivation to E. coli-derived asparaginase.

What it is used for

  • Acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) as a component of multi-agent chemotherapy
  • Adults and children aged 1 month and older who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase

Dosing

  • Every 48 hours: 25 mg/m2 intramuscularly or intravenously
  • Alternatively Monday/Wednesday/Friday: 25 mg/m2 on Monday and Wednesday and 50 mg/m2 on Friday (routes as given in the full text)
  • With intravenous use, premedication with paracetamol, an H1 and an H2 receptor blocker should be considered
  • Trough serum asparaginase activity should be monitored and the schedule adapted if needed
  • Only by personnel experienced with antineoplastics, with anaphylaxis treatment available

Contraindications

  • History of severe hypersensitivity reactions to the active substance
  • Severe pancreatitis or history of severe pancreatitis during previous asparaginase therapy
  • Severe thrombosis or severe haemorrhagic events during previous asparaginase therapy

Important warnings

  • Grade 3 and 4 hypersensitivity reactions have occurred; may be more frequent with intravenous use
  • Pancreatitis, thrombosis and haemorrhage can occur
  • Hepatotoxicity: monitor bilirubin and transaminases before and during treatment
  • Asparaginase activity varies substantially between patients; level monitoring is required

Side effects

  • Most common: anaemia, vomiting, thrombocytopenia, neutropenia, nausea, febrile neutropenia, fatigue, pyrexia
  • Also common: decreased appetite, increased transaminases, abdominal pain, headache, diarrhoea
  • Most frequent serious reactions: febrile neutropenia, pyrexia, vomiting, sepsis, hypersensitivity, pancreatitis

Interactions

  • No interaction studies; asparaginase may increase toxicity of other medicines through effects on liver function
  • Vincristine: asparaginase given concurrently or immediately before may increase vincristine toxicity
  • An indirect interaction with oral contraceptives cannot be ruled out; non-hormonal contraception should be used

Pregnancy and breastfeeding

  • Can cause foetal harm; men and women use effective contraception during and for at least 3 months after treatment
  • No breast-feeding during therapy and for two weeks after the last dose

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • EnrylazeJazz Pharmaceuticals Ireland Limited · EMEA/H/C/005917

Source: European Medicines Agency (EMA), product information

Germany

  • ErwinasePorton Biopharma Limited · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Turkey

  • Leunase EnjektablONKO İLAÇ SAN. VE TİC. A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 10 more European countries
Belgium
Erwinase
Denmark
Erwinase
Finland
Erwinase
France
Erwinase
Ireland
Erwinase
Netherlands
Erwinase
Norway
Erwinase
Portugal
Erwinase
Spain
Erwinase
Sweden
Erwinase

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Enrylaze – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/enrylaze-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.